Related Experiment Video
Updated: May 31, 2026

10:39
Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding
Published on: August 30, 2024
Pulmonary artery banding: still a valuable option in developing countries?
Andre Brooks1, Agneta Geldenhuys, Liesl Zuhlke
1Christiaan Barnard Division of Cardiothoracic Surgery, Red Cross Children's Hospital, University of Cape Town, Cape Town, South Africa. andre.brooks@uct.ac.za
Summary
Pulmonary artery banding (PAB) to defer high-risk biventricular repair in developing countries is ineffective due to poor compliance and high mortality. Early definitive repair is recommended even for high-risk patients.
Area of Science:
- Pediatric Cardiology
- Congenital Heart Disease Surgery
- Global Health
Background:
- Pulmonary artery banding (PAB) is used to defer high-risk biventricular repair in pediatric patients.
- Socio-economic factors in developing countries may impact the efficacy of staged surgical approaches.
Purpose of the Study:
- To evaluate the effectiveness of PAB in deferring biventricular repair for high-risk patients in a developing country.
- To assess outcomes including mortality, re-admission, growth, and definitive repair rates.
Main Methods:
- Retrospective cohort analysis of 143 consecutive patients undergoing PAB between 2002 and 2007.
- Patients were considered high-risk for immediate biventricular repair.
- Follow-up data collected until January 2010, with a minimum of 2 years post-PAB.
Main Results:
- Total mortality was 29% (42/143), with 21% inter-stage mortality.
- 50% of patients did not show positive growth post-banding.
- Only 43% (62/143) achieved definitive biventricular repair; 57% remained uncorrected.
Conclusions:
- PAB as a strategy to defer biventricular repair is largely ineffective in developing countries, primarily due to poor patient compliance.
- High inter-stage mortality and unreliable follow-up compromise the benefits of this approach.
- Early definitive biventricular repair should be considered even for high-risk pediatric patients.

